 WAYNE, Pa., June 09, 2021 GLOBE NEWSWIRE -- Aclaris Therapeutics, Inc. Nasdaq:ACRS, a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,042,254 shares of its common stock at a price to the public of 17.75 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 1,056,338 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately 125.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters option. The offering is expected to close on or about June 14, 2021, subject to customary closing conditions. 